Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans

被引:90
作者
Bennett, LAT
Johnson, JM [1 ]
Stephens, DP
Saad, AR
Kellogg, DL
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA
[3] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78284 USA
来源
JOURNAL OF PHYSIOLOGY-LONDON | 2003年 / 552卷 / 01期
关键词
D O I
10.1113/jphysiol.2003.042135
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Active vasodilatation (AVD) in human, non-glabrous skin depends on functional cholinergic fibres but not on acetylcholine (ACh). We tested whether AVD is a redundant system in which ACh and vasoactive intestinal polypeptide (VIP) are co-released from cholinergic nerves. (1) We administered VIP by intradermal microdialysis to four discrete areas of skin in the presence of different levels of the VIP receptor antagonist, VIP(10-28), also delivered by microdialysis. Skin blood flow (SkBF) was continuously monitored by laser Doppler flowmetry (LDF). Mean arterial pressure (MAP) was measured non-invasively and cutaneous vascular conductance (CVC) calculated as LDF/MAP. Subjects were supine and wore water-perfused suits to control whole-body skin temperature (T-sk) at 34degreesC. Concentrations of 54 mum, 107 mum, or 214 mum VIP(10-28) were perfused via intradermal. microdialysis at 2 mul min(-1) for approximately I h. Then 7.5 mum VIP was added to the perfusate containing VIP (10-28) at the three concentrations or Ringer solution and perfusion was continued for 45-60 min. At the control site, this level of VIP caused approximately the vasodilatation typical of heat stress. All VIP(10-28)-treated sites displayed an attenuated dilatation in response to the VIP. The greatest attenuation was observed at the site that received 214 mum VIP(10-28) (P < 0.01). (2) We used 214 mum VIP(10-28) alone and with the iontophoretically administered muscarinic receptor antagonist atropine (400 muA cm(-2), 45s, 10 mm) in heated subjects to test the roles of VIP and ACh in AVD. Ringer solution and 214 mum VIP(10-28) were each perfused at two sites, one of which in each case was pretreated with atropine. After I h of VIP(10-28) treatment, individuals underwent 45-60 min of whole-body heating (T-sk to 38.5degreesC). VIP(10-28), alone or in combination with atropine, attenuated the increase in CVC during heat stress, suggesting an important role for VIP in AVD.
引用
收藏
页码:223 / 232
页数:10
相关论文
共 47 条
[1]  
AGGESTRUP S, 1983, GASTROENTEROLOGY, V84, P924
[2]   CHANGES IN SKIN CIRCULATION AFTER INSERTION OF A MICRODIALYSIS PROBE VISUALIZED BY LASER-DOPPLER PERFUSION IMAGING [J].
ANDERSON, C ;
ANDERSSON, T ;
WARDELL, K .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (05) :807-811
[3]  
CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392
[4]   VASOACTIVE-INTESTINAL-PEPTIDE (VIP) AND PEPTIDE HISTIDINE METHIONINE (PHM) IN HUMAN ECCRINE SWEAT GLANDS - DEMONSTRATION OF INNERVATION, SPECIFIC BINDING-SITES AND PRESENCE IN SECRETIONS [J].
EEDY, DJ ;
SHAW, C ;
ARMSTRONG, EP ;
JOHNSTON, CF ;
BUCHANAN, KD .
BRITISH JOURNAL OF DERMATOLOGY, 1990, 123 (01) :65-76
[5]   BRADYKININ FORMATION IN HUMAN SKIN AS A FACTOR IN HEAT VASODILATATION [J].
FOX, RH ;
HILTON, SM .
JOURNAL OF PHYSIOLOGY-LONDON, 1958, 142 (02) :219-232
[6]   CARDIOVASCULAR EFFECTS OF VASOACTIVE-INTESTINAL-PEPTIDE IN HEALTHY-SUBJECTS [J].
FRASE, LL ;
GAFFNEY, FA ;
LANE, LD ;
BUCKEY, JC ;
SAID, SI ;
BLOMQVIST, CG ;
KREJS, GJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 60 (16) :1356-1361
[7]   NONINVASIVE BLOOD-PRESSURE MONITORING DURING HEAD-UP TILT USING THE PENAZ PRINCIPLE [J].
FRIEDMAN, DB ;
JENSEN, FB ;
MATZEN, S ;
SECHER, NH .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1990, 34 (07) :519-522
[8]  
Grant RT, 1938, CLIN SCI, V3, P273
[9]  
GRIDER JR, 1990, J PHARMACOL EXP THER, V253, P738
[10]   VIP-IMMUNOREACTIVITY IN THE SKIN OF VARIOUS MAMMALS - IMMUNOHISTOCHEMICAL, RADIOIMMUNOLOGICAL AND EXPERIMENTAL-EVIDENCE FOR A DUAL LOCALIZATION IN CUTANEOUS NERVES AND MERKEL CELLS [J].
HARTSCHUH, W ;
REINECKE, M ;
WEIHE, E ;
YANAIHARA, N .
PEPTIDES, 1984, 5 (02) :239-245